Elidel Sales To Rebound In Early 2006 Despite Cancer Risk Concerns – Novartis
This article was originally published in The Pink Sheet Daily
Executive Summary
Elidel sales should rebound in early 2006 from their recent decline resulting from concerns over the eczema treatment's potential cancer risk, Novartis Pharmaceuticals CEO Paolo Costa said March 15